๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Pathogenesis of Pediatric Obsessive-compulsive Disorder: Based on the Microbiota-gut-brain Axis
NCT06754319Obsessive-Compulsive Disorder, Tic Disorder
Shanghai Mental Health Center
Observational
125
Shanghai
2024-08-24
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783Breast Cancer, Solid Tumor
DrugBL-M17D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Harbin, Shanghai
2024-08-24
Recruiting
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
NCT06592326Urothelial Carcinoma
Drugs9MW2821·Cisplatin/carboplatin·Gemcitabine·Tislelizumab
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3
460
Shanghai
2024-08-22
Active, closed
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
NCT06530849Refractory Systemic Lupus Erythematosus
DrugAZD0120
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
20
Shanghai, Wuhan
2024-08-22
By invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
GrandPharma (China) Co., Ltd.
Observational
100
Guangzhou, Jinan, Xiโ€™an, Beijing, Shanghai
2024-08-22
Recruiting
Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
NCT07399210Lung Cancer (Diagnosis), Fragmentomics
Baohui Han
Observational
240
Shanghai
2024-08-21
Active, closed
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
NCT06449027Breast Cancer Subjects
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
211
Shanghai
2024-08-21
Recruiting
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment
NCT07711171Type 2 Diabetes Mellitus, Cognitive Impairment
DrugsAcarbose·Sitagliptin
Fudan University
Phase 4
60
Shanghai
2024-08-19
Not yet open
Effects of Napping in Pregnant Women With Sleep Disturbances on Offspring Neurodevelopment
NCT06514833Sleep
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
80
Shanghai
2024-08-19
Recruiting
Trial of JMKX003801 in Healthy Participants
NCT06549309Healthy
Jemincare
Phase 1
70
Shanghai
2024-08-17
Active, closed
Novel Lenses for Myopia Progression Trial
NCT06563700Myopia, Progressive
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
342
Shanghai
2024-08-16
By invitation
Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
NCT06962449Non-Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer Stage IV
Shanghai Chest Hospital
Observational
500
Shanghai
2024-08-16
By invitation
Evaluating the Safety and Efficacy of Prosthetic Polymer Heart Valves for the Treatment of Aortic Valve Disease
NCT06518681Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Regurgitation
Suzhou Hearthill Medical Technology Co.,LTD
Not applicable
10
Shanghai
2024-08-15
Not yet open
OXiris for Abdominal SEptic Shock (OASES Study)
NCT06504316Septic Shock, Abdominal Sepsis, Multi Organ Failure, Blood Purification
RenJi Hospital
Not applicable
192
Shanghai
2024-08-15
Recruiting
Electroencephalography in the Management of Neuroelectric Stimulation in Patients With Severe Traumatic Brain Injuries
NCT06571032Brain Injuries
RenJi Hospital
Observational
50
Shanghai
2024-08-15
Not yet open
Clinical Study of FB1001 in Patients
NCT06506305Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy, APAC - Acute Primary Angle Closure, Glaucoma, Angle-Closure
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1
59
Shanghai
2024-08-15
Recruiting
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
NCT07110883Advanced Solid Tumor
DrugSYS6023
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
400
Harbin, Shanghai
2024-08-15
Recruiting
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
NCT06561555Mammary or Extramammary Paget's Disease
Fudan University
Phase 2
36
Shanghai
2024-08-15
Active, closed
Medication Adherence to Phone-supervised Pancreatic Enzyme Replacement Therapy
NCT06581653Chronic Pancreatitis, Pancreatic Exocrine Insufficiency
Changhai Hospital
Not applicable
204
Shanghai
2024-08-15
Recruiting
MRSI Evaluation for Minor Stroke With Large Vessel Occlusion
NCT06457217Acute Ischemic Stroke
Shanghai 6th People's Hospital
Observational
75
Shanghai
2024-08-15
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Shanghai, Changchun, Beijing
2024-08-15
By invitation
Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke
NCT06551727Stroke, Ischemic
Ruijin Hospital
Not applicable
70
Shanghai
2024-08-15
Active, closed
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
NCT06492915Pancreatic Ductal Adenocarcinoma
DrugsChiauranib·Albumin paclitaxel·Gemcitabine
Chipscreen Biosciences, Ltd.
Phase 2
42
Shanghai
2024-08-13
Recruiting
Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial
NCT06553053Crohn's Disease Relapse, Inflammatory Bowel Diseases
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Not applicable
106
Shanghai
2024-08-13
Recruiting
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
NCT06840665Locally Advanced Rectal Cancer
Fudan University
Phase 2
46
Shanghai
2024-08-13
Recruiting
Bolt CSP-M Holter Study
NCT06540521Heart Failure, Bradycardia
Medtronic Cardiac Rhythm and Heart Failure
Observational
75
Shanghai, Hangzhou
2024-08-13
Recruiting
Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis
NCT06503692Arteriovenous Graft Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
140
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai
2024-08-13
Not yet open
Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy
NCT06568445Bronchial Asthma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
90
Shanghai
2024-08-12
Recruiting
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
NCT06555068Advanced Unresectable or Metastatic Breast Cancer
DrugsHRS-1358·HRS-6209·HRS-8080·Letrozole
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
528
Shanghai
2024-08-12
Recruiting
A Real World Study of Sacituzumab Govitecan
NCT06966141Breast Cancer Metastatic, Treatment Outcome
Fudan University
Observational
100
Shanghai
2024-08-12
Recruiting
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
NCT06519526Relapsed/Refractory Peripheral T Cell Lymphoma
Fudan University
Phase 2
25
Shanghai
2024-08-12
Recruiting
Hepatic Safety of Statin Use in Neurology Inpatients
NCT06592196Statin Adverse Reaction
Shanghai Yueyang Integrated Medicine Hospital
Observational
2,000
Shanghai
2024-08-10
Recruiting
Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion
NCT06550622Hepatitis B, Chronic
Huashan Hospital
Observational
300
Shanghai
2024-08-10
Not yet open
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
NCT06531291ESCC, Biliary Tract Cancer, Gastric Cancer, Pancreas Cancer
DrugsSurufatinib·Serplulimab
RenJi Hospital
Phase 2
80
Shanghai
2024-08-10
Active, closed
The Basophil Activation Test For Egg Allergy
NCT06559319Food Allergy
Xia Peng
Observational
174
Shanghai
2024-08-10
Recruiting
Efficacy and Safety of Rifaximin in Treating MAFLD
NCT07185932Metabolic-associated Fatty Liver Disease
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
40
Shanghai
2024-08-10
Active, closed
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT06519370Triple Negative Breast Cancer
DrugsVinorelbine·Eribulin·Capecitabine·Gemcitabine
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 3
350
Shanghai
2024-08-09
Recruiting
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
NCT06520488Advanced Solid Tumors
DrugHRS-4642
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
118
Shanghai
2024-08-09
Recruiting
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
NCT06182969SLE
DrugLisaftoclax
Ascentage Pharma Group Inc.
Phase 1/2
40
Shanghai
2024-08-09
Recruiting
The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma
NCT06401772Chronic Subdural Hematoma, Recurrence
Huashan Hospital
Not applicable
830
Shanghai
2024-08-08
Recruiting
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
NCT06311981Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect
Jian Chen
Phase 2
29
Shanghai
2024-08-08
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
NCT06598722Lymphoblastic Lymphoma, Adult, Lymphoblastic Leukemia, Acute T-cell
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
206
Shanghai
2024-08-07
Active, closed
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109Alopecia Areata
DrugRitlecitinib
Pfizer
Observational
450
Beijing, Changchun, Changsha, Guangzhou, Shanghai
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab Deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-08-07
Active, closed
Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis
NCT07079462Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET
Fudan University
Phase 2
40
Shanghai
2024-08-07
Recruiting
Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
NCT06427447Pancreatic Cancer
Changhai Hospital
Phase 3
770
Shanghai
2024-08-06
Active, closed
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNฮฑ Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563For Treatment of Chronic Hepatitis B Virus Infection
DrugsBRII-179·Elebsiran·PEG-IFNฮฑ
Brii Biosciences Limited
Phase 2
150
Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-08-06
Recruiting
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
NCT06487455Advanced Solid Tumor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
ADC-induced Neurotoxicity Treated With Duloxetine
NCT06551051Solid Tumour
Fudan University
Phase 2
37
Shanghai
2024-08-06
Active, closed
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
NCT06519721Hepatocellular Carcinoma
DrugLenvatinib
RenJi Hospital
Not applicable
12
Shanghai
2024-08-06
Recruiting
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
NCT06349980Carcinoma, Hepatocellular
DrugsHLX04·Serplulimab
Shanghai Henlius Biotech
Phase 2
117
Shanghai
2024-08-05
Recruiting
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
NCT06638866Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
Changhai Hospital
Observational
5,000
Shanghai, Jiaxing, Ningbo
2024-08-03
Recruiting
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
NCT06534463Marginal Zone Lymphoma
Ruijin Hospital
Observational
500
Shanghai
2024-08-02
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
NCT06471205Triple-negative Breast Cancer
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
52
Shanghai
2024-08-02
Recruiting
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
NCT06505824Small Cell Lung Cancer, Neuroendocrine Tumors
DrugBL-M14D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Shanghai
2024-08-02
Active, closed
A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher Disease
NCT06528080Gaucher Disease
Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
3
Shanghai
2024-08-01
Recruiting
Effectiveness of MST Versus ECT for Major Depressive Episode
NCT06409325Major Depressive Disorder (MDD)
Shanghai Mental Health Center
Not applicable
210
Shanghai
2024-08-01
Active, closed
A Phase 2 Trial of JKN24011 in COPD
NCT07440524COPD (Chronic Obstructive Pulmonary Disease)
Joincare Pharmaceutical Group Industry Co., Ltd
Phase 2
215
Shanghai
2024-08-01
Recruiting
Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer
NCT06515587PDAC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
40
Shanghai
2024-08-01
Recruiting
Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients
NCT06566898Pneumonia, Next-generation Sequencing, Microbiome, Antimicrobial Resistance
Shanghai General Hospital, China
Observational
800
Shanghai
2024-08-01
Recruiting
Study on the Feelings of Euphoria Caused by Remimazolam During Gastroscopy and Colonoscopy and Their Related Factors
NCT06721195Euphoria, Remimazolam Besylate, Gastrointestinal Endoscopy
Zhangjie Yu
Observational
305
Shanghai
2024-08-01
Not yet open
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
NCT06510465Breast Cancer
DrugsUtidelone·Pertuzumab·Trastuzumab·Cisplatin
RenJi Hospital
Phase 2
143
Shanghai
2024-08-01
Recruiting
Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
NCT06519578Hepatocellular Carcinoma
RenJi Hospital
Not applicable
1,115
Shanghai
2024-08-01
Recruiting
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
NCT06517511Diffuse Large B Cell Lymphoma
DrugsR-CHOP Protocol·R-Chop·Selinexor
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
NCT06541340Pancreatic Cancer, Obstructive Jaundice
Ruijin Hospital
Not applicable
360
Shanghai
2024-08-01
Recruiting
A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
NCT06677879Breast Cancer
Shanghai Proton and Heavy Ion Center
Phase 2
780
Shanghai
2024-08-01
Recruiting
Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
NCT06537908Hepatocellular Carcinoma
DrugAnti-VEGF
Shanghai Zhongshan Hospital
Observational
50
Shanghai
2024-08-01
Not yet open
A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer
NCT06541288Uterine Cervical Neoplasms
Obstetrics & Gynecology Hospital of Fudan University
Not applicable
230
Shanghai
2024-08
Recruiting
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06498986Non-small Cell Lung Cancer
DrugsIza-bren·Osimertinib
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
40
Shanghai
2024-07-31
Recruiting
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
NCT06331169Breast Cancer
DrugsTrastuzumab deruxtecan·Dexamethasone
Fudan University
Phase 1
42
Shanghai
2024-07-31
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Active, closed
The Intervention Effect and Potential Neural Mechanisms of Music Therapy in Children and Adolescents With Mood Disorders
NCT06756698Mood Disorders in Children and Adolescents
Shanghai Mental Health Center
Not applicable
54
Shanghai
2024-07-31
Active, closed
A Real-world Study to Evaluate the Effectiveness of Intravascular Lithotripsy in Moderate to Severe Calcification Lesion of Lower Extremity Femoropopliteal Artery
NCT06636968Peripheral Arterial Disease
Shanghai Zhongshan Hospital
Observational
200
Shanghai
2024-07-31
Active, closed
SAVE-PCI: NyokAssistโ„ข Small-Bore VAD vs. IABP in Elective High-Risk PCI
NCT07010965High-Risk PCI
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Recruiting
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06587425Gastric or Gastroesophageal Junction Adenocarcinoma
DrugsCandonilimab·LM-302·Capecitabine
Shanghai Zhongshan Hospital
Phase 2
50
Shanghai
2024-07-31
Recruiting
Efficacy of Two HMOs in Chinese Infants
NCT06361719Healthy Infants
Sociรฉtรฉ des Produits Nestlรฉ (SPN)
Not applicable
262
Shanghai
2024-07-29
Recruiting
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
NCT06522555Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Phase 3
100
Shanghai
2024-07-29
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207Multiple Myeloma
DrugIBI3003
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Recruiting
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
NCT06430437Non-Small Cell Lung Cancer With HER2- Mutations
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
300
Shanghai
2024-07-29
Recruiting
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT06492005Triple-Negative Breast Cancer
DrugsPD-1 inhibitior·9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
160
Shanghai
2024-07-26
Recruiting
Efficacy and Influencing Factors of Deep Transcranial Magnetic Stimulation in the Treatment of OCD
NCT06692114Obsessive-Compulsive Disorder
Zhen Wang
Not applicable
70
Shanghai
2024-07-26
Recruiting
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy
NCT06641895Duchenne Muscular Dystrophy (DMD)
Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
6
Shanghai
2024-07-25
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Recruiting
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
NCT07093970Advanced Solid Tumors
DrugMRG006A
Lepu Biopharma Co., Ltd.
Phase 1/2
343
Beijing, Shanghai
2024-07-24
Recruiting
Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
NCT06787911Thyroid Cancer
Yu Wang
Phase 2
14
Shanghai
2024-07-24
Recruiting
PulseSelectโ„ข PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, รœrรผmqi
2024-07-23
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NCT06764836Advanced Solid Tumors, HCC
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1
108
Shanghai
2024-07-23
Recruiting
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
NCT06755775Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Observational
150
Shanghai
2024-07-23
Active, closed
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms
AstraZeneca
Observational
532
Shanghai
2024-07-23
Recruiting
The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life
NCT06535087Pediatric Asthma, Rhinitis, Allergic, Quality of Life
Wenjing Zhou
Observational
600
Shanghai
2024-07-20
Recruiting
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
NCT07291063Cholangiocarcinoma
Shanghai Zhongshan Hospital
Observational
50
Shanghai
2024-07-19
Recruiting
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
NCT06623487Carcinoma, Non-Small-Cell Lung, PET / CT, Neoadjuvant Immunotherapy
Ruijin Hospital
Observational
30
Shanghai
2024-07-19
Active, closed
aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial
NCT06288659Aneurysmal Subarachnoid Hemorrhage, Intacranial Hypertension
Huashan Hospital
Not applicable
372
Shanghai
2024-07-19
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323Asthma
DrugDepemokimab
GlaxoSmithKline
Phase 3
150
Guangzhou, Shanghai, Tianjin
2024-07-19
Recruiting
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT06517004Diffuse Large B Cell Lymphoma
Fudan University
Phase 1
9
Shanghai
2024-07-18
Recruiting
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
NCT06530316Thyroid Cancer
Fudan University
Observational
48
Shanghai
2024-07-18
Active, closed
Open, Randomized Crossover Study on PK, PD, Biopotency, and Bioavailability of Insulin Capsules in Healthy Chinese Males
NCT06519604Diabete Mellitus
DrugHuman Insulin
Shanghai Jiao Tong University School of Medicine
Phase 1
20
Shanghai
2024-07-17
Recruiting
Inhaled Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Post-Infectious Cough: A Single-Center Randomized Controlled Clinical Trial
NCT07103980Post-Infectious Cough
Shanghai Changzheng Hospital
Phase 1/2
40
Shanghai
2024-07-16
Rows per page Showing 2301–2400 of 3827
Previous 22 23 24 25 26 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=24

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.